Neuropharmacological and neurochemical properties of N-(2-cyanoethyl)-2-phenylethylamine, a prodrug of 2-phenylethylamine.
1 N-(2-cyanoethyl)-2-phenylethylamine (CEPEA) was examined as a possible prodrug of 2-phenylethylamine (PEA). 2 Pharmacokinetics of PEA and CEPEA were investigated in rat brain, blood and liver by gas chromatography with electron-capture detection (GC-ECD). Interactions of PEA and CEPEA with putative neurotransmitter amines were investigated by use of high performance liquid chromatography with electrochemical detection (h.p.l.c.-e.c.). 3 Administration of PEA caused transient increases in PEA concentrations which decreased rapidly in brain and blood and at a slower rate in liver. Administration of CEPEA caused sustained elevations of PEA concentrations and elimination of PEA was markedly decreased in these tissues relative to the situation after administration of PEA itself. 4 Administration of CEPEA caused more prolonged decreases in brain noradrenaline, dopamine and 5-hydroxytryptamine concentrations than those observed after PEA administration, although values increased to control levels eventually.
D000818:Animals; D001921:Brain / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D002395:Catecholamines / Q000378:metabolism; D002849:Chromatography, Gas; D004563:Electrochemistry; D008099:Liver / Q000378:metabolism; D008297:Male; D008995:Monoamine Oxidase / Q000378:metabolism; D018377:Neurotransmitter Agents / Q000378:metabolism*; D010599:Pharmacokinetics; D010627:Phenethylamines / Q000097:blood / Q000493:pharmacokinetics* / Q000494:pharmacology; D011355:Prodrugs / Q000097:blood / Q000493:pharmacokinetics*; D051381:Rats; D011919:Rats, Inbred Strains
D002395:Catecholamines; D018377:Neurotransmitter Agents; D010627:Phenethylamines; D011355:Prodrugs; C054163:N-(2-cyanoethyl)-2-phenylethylamine; C029261:phenethylamine; D008995:Monoamine Oxidase